Testing medications in children

New England Journal of Medicine

Volumn 347, Issue 18, 2002, Pages 1462-1470

  Steinbrook, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ATORVASTATIN; AURALGAN; BETAMETHASONE DIPROPIONATE; BUSPIRONE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIETHYLENE GLYCOL; ETODOLAC; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; HYPNOTIC SEDATIVE AGENT; LORATADINE; METFORMIN; METHYLPHENIDATE; MIDAZOLAM; OMEPRAZOLE; ORCIPRENALINE; PIMECROLIMUS; PROMETHAZINE; PROPOFOL; REBETRON; SERTRALINE; SEVOFLURANE; SULFANILAMIDE; THALIDOMIDE; UNINDEXED DRUG;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; AGGRESSION; ANESTHESIA; ARTICLE; ATOPIC DERMATITIS; BEHAVIOR DISORDER; CHILD; CHILD HEALTH CARE; CHILDHOOD DISEASE; CHRONIC HEPATITIS; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG INTOXICATION; DRUG LABELING; DRUG MONITORING; DRUG RESEARCH; DRUG SAFETY; ECZEMA; FEVER; FOOD AND DRUG ADMINISTRATION; GROWTH DISORDER; HEPATITIS C; HOSTILITY; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL ETHICS; MENTAL DISEASE; PEDIATRIC ANESTHESIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SEDATION; SEIZURE; SKIN ATROPHY; SUICIDE ATTEMPT;

BIOMEDICAL AND BEHAVIORAL RESEARCH; LEGAL APPROACH;

CHILD; CLINICAL TRIALS; DRUG EVALUATION; ETHICS, RESEARCH; HUMAN EXPERIMENTATION; HUMANS; LEGISLATION, DRUG; PATENTS; PEDIATRICS; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037206361     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMhpr021646     Document Type: Article

References (57)

1. Elixir of sulfanilamide-massengill: Chemical, pharmacologic, pathologic and necropsy reports: Preliminary toxicity reports on diethylene glycol and sulfanilamide. JAMA 1937;109:1531-9.
2. Geiling EMK, Cannon PR. Pathologic effects of elixir of sulfanilamide (diethylene glycol) poisoning. JAMA 1938;111:919-26.
3. Kauffman RE. Drug safety, testing, and availability, for children. Child Legal Rights J 1998;18(2):27-34.
4. 't Jong GW, Vulto AG, de Hoog M, Schimmel KJM, Tibboel D, van den Anker JN. Unapproved and off-label use of drugs in a children's hospital. N Engl J Med 2000;343:1125.
5. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000;320:79-82.
6. Bücheler R, Schwab M, Mörike K, et al. Off label prescribing to children in primary care in Germany: Retrospective cohort study. BMJ 2002;324:1311-2.
7. Schirm E, Tobi H, de Jong-van den Berg LTW. Unlicensed and offlabel drug use by children in the community: Cross sectional study. BMJ 2002;324:1312-3.
8. 't Jong GW, Eland IA, Sturkenboom MCJM, van den Anker JN, Stricker BHC. Unlicensed and off label prescription of drugs to children: Population based cohort study. BMJ 2002;324:1313-4.
9. Survey Finds 194 Medicines in Development for Children. Press release of the Pharmaceutical Research and Manufacturers of America, Washington, D.C., May 29, 2002.
10. Food and Drug Administration Modernization Act of 1997, Pub. L. 105-115, 105th Cong. (Nov. 21, 1997).
11. Department of Health and Human Services, Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients; final rule. Fed Regist 1998;63(231):66632-72.
12. Association of American Physicians & Surgeons, Inc., Competitive Enterprise Institute, and Consumer Alert v. Food and Drug Administration and Department of Health and Human Services, civil action 00-02898 (U.S. D.D.C., filed Dec. 4, 2000).
13. Connolly C. FDA to suspend a rule on child drug testing: Agency says patent plan meets safety goal. Washington Post. March 19, 2002:A10.
14. The need to test drugs on children. New York Times. April 7, 2002(Section 4):14.
15. Kaufman M, Connolly C. U.S. backs pediatric tests in reversal on drug safety. Washington Post. April 20, 2002:A3.
16. HHS Launches New Pediatric Drug Safety Initiative. Press release of the Department of Health and Human Services, Washington, D.C., April 19, 2002.
17. Rosato J. The ethics of clinical trials: A child's view. J Law Med Ethics 2000;28:362-78.
18. Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995;95:286-94.
19. Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999;104:Suppl:607-9.
20. Drug Trend Report. Franklin Lakes, N.J.: Medco Health Solutions, September 2002.
21. Coté CJ, Kauffman RE, Troendle GJ, Lambert GH. Is the "therapeutic orphan" about to be adopted? Pediatrics 1996;98:118-23.
22. Wilson JT. An update on the therapeutic orphan. Pediatrics 1999;104:Suppl:585-90.
23. Blumer JL. Off-label uses of drugs in children. Pediatrics 1999;104:Suppl:598-602.
24. Department of Health and Human Services, Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs: Revision of "pediatric use" subsection in the labeling: Final rule (21 C.F.R. part 201). Fed Regist 1994;59:64240.
25. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research Involving Children. Washington, D.C.: Government Printing Office, 1977. (DHEW publication no. (OS) 77-0004.)
26. Committee on Bioethics. Informed consent, parental permission, and assent in pediatric practice. Pediatrics 1995;95:314-7.
27. Department of Health, Education and Welfare. Protection of human subjects - Proposed regulations on research involving children. Fed Regist 1978;43:31786.
28. Protection of Human Subjects, subpart D - additional protections for children involved as subjects in research, 45 C.F.R. §46.401-09.
29. Department of Health and Human Services, Food and Drug Administration. Additional safeguards for children in clinical investigations of FDA-regulated products. Fed Regist 2001;66(79):20589-600.
30. Steinbrook R. Improving protection for research subjects. N Engl J Med 2002;346:1425-30. [Erratum, N Engl J Med 2002;346:1838.]
31. Dembner A, Dangerous dosage to make pediatric medicine safer, thousands of children are being used to test drugs originally designed for adults: Tragically, the side effects can sometimes prove deadly. Boston Globe. February 18, 2001:A1.
32. Idem. Teddy bears and veiled threats. Boston Globe. March 20, 2001:A1.
33. Idem. Who's protecting the children? Drug research raises concerns about policy and penalties. Boston Globe. March 25, 2001:A1.
34. Stolberg SG. Children test new medicines despite doubts. New York Times. February 11, 2001(Section 1):1.
35. Zimmerman R. Desperately seeking kids for clinical trials. Wall Street Journal. May 29, 2002:D1.
36. Department of Health and Human Services. Proposed recommendations regarding support of research protocol: Precursors to diabetes in Japanese American youth. Fed Regist 2002;67(152):51283-4.
37. Report on Expert Panel Review Under Subpart D of 45 C.F.R. 46: Precursors to Diabetes in Japanese American Youth. Rockville, Md.: Office for Human Research Protections, August 2001.
38. Kaiser J. Ethicists fault review of children's study. Science 2002;297:1461.
39. Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996;88:812-6.
40. Children's Health Act of 2000, Pub. L. 106-310, tit. 27, §2701, 106th Cong. (Oct. 17, 2000).
41. Best Pharmaceuticals for Children Act, Pub. L. 107-109, 107th Cong. (Jan. 4, 2002).
42. Department of Health and Human Services, Food and Drug Administration. Obtaining timely pediatric studies of and adequate pediatric labeling for human drugs and biologics. Fed Regist 2002;67(79):20070-2.
43. To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients, S. 2394, introduced in the Senate April 29, 2002.
44. To amend the Federal Food, Drug, and Cosmetic Act to require labeling containing information applicable to pediatric patients, H.R. 4730, introduced in the House May 14, 2002.
45. Food and Drug Administration. The Pediatric Exclusivity Provision: January 2001 Status Report to Congress. Washington, D.C.: Department of Health and Human Services, 2001.
46. Center for Drug Evaluation and Research. Frequently Asked Questions on Pediatric Exclusivity (505A), the Pediatric "Rule," and Their Interaction. Washington, D.C.: Food and Drug Administration, 2001. (Accessed October 10, 2002, at http://www.fda.gov/cder/pediatric/faqs.htm.)
47. Approved Active Moieties to Which FDA has Granted Pediatric Exclusivity for Pediatric Studies Under Section 505A of the Federal Food, Drug, and Cosmetic Act. Washington, D.C.: Food and Drug Administration, 2002. (Accessed October 10, 2002, at http://www.fda.gov/cder/pediatric/exgrant.htm.)
48. US Top 10 Products by Prescriptions. Fairfield, Conn.: IMS Health, 2002. (Accessed October 10, 2002, at http://www.imshealth.com/public/structure/dispcontent /1,2779,1343-1343-144004,00.html.)
49. Pediatric Exclusivity Labeling Changes as of September 10, 2002. (Accessed October 10, 2002, at http://www.fda.gov/cder/pediatric/labelchange.htm.)
50. CDER 2001 Report to the Nation: Improving Public Health Through Human Drugs. Rockville, Md.: FDA Center for Drug Evaluation and Research, 2002.
51. Letter From AstraZeneca Pharmaceticals to Health Care Providers. Wilmington, Del.: AstraZeneca Pharmaceuticals, March 26, 2001.
52. Zimmerman R. Child play: Pharmaceutical firms win big on plan to test adult drugs on kids. Wall Street Journal. February 5, 2001:A1.
53. Heinrich J. Pediatric Drug Research: Substantial Increase in Studies of Drugs for Children, But Some Challenges Remain. Testimony Before the Committee on Health, Education, Labor and Pensions, U.S. Senate. Washington, D.C.: General Accounting Office, May 8, 2001. (GAO-01-705T.)
54. Ward R. More accurate doses for a child's medicine. Wall Street Journal. February 16, 2001:A11.
55. Franson TR. Testimony on Behalf of the Pharmaceutical Research and Manufacturers of America Before the Energy and Commerce Subcommittee on Health. Washington, D.C.: House of Representatives, May 3, 2001.
56. Codification of the Pediatric Rule: Background and Recommendations From the American Pediatric Society, Association of Medical School Pediatric Department Chairs, American Academy of Pediatrics, Elizabeth Glaser Pediatric AIDS Foundation, Society for Adolescent Medicine, Society for Pediatric Research. Washington, D.C.: Elizabeth Glaser Pediatric AIDS Foundation, June 2002.
57. Pina LM. Center IDs top 10 drugs used off-label in out-patient setting. News Along the Pike. January 17, 1997:6-7. (Rockville, Md.: FDA Center for Drug Evaluation and Research.)